Literature DB >> 28088469

Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1.

Marianne S Andresen1, Huda Omar Ali2, Christiane Filion Myklebust1, Per Morten Sandset2, Benedicte Stavik1, Nina Iversen3, Grethe Skretting4.   

Abstract

Hormone-sensitive cancers can be influenced by estrogens, a process usually mediated through the estrogen receptor (ER). Tissue factor pathway inhibitor type 2 (TFPI-2) is a Kunitz-type serine protease inhibitor involved in regulating the extracellular matrix. The present study demonstrates that the expression of TFPI-2 can be induced by estrogens. Breast cancer data from GOBO displayed increased levels of TFPI-2 and increased survival in patients with ERα+ tumors. Treatment of MCF7 cells (ERα+) with 17β-estradiol (E2) or 17α-ethinyl estradiol (EE2) increased TFPI-2 mRNA and protein levels. This effect was mitigated with fulvestrant and by knocking down ERα, indicating that estrogen mediated TFPI-2 induction was through ERα. Upon knock down of DNA cytosine-5 methyltransferase 1 (DNMT1) or lysine-specific demethylase 1 (LSD1) in MCF7 cells, reduced effect of E2 on TFPI-2 mRNA levels was observed. Our data thus suggest that estrogen induced TFPI-2 expression in MCF7 cells is mediated by ERα and also by the action of LSD1.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Demethylation; ERα; Estrogen; LSD1; MCF7 cells; TFPI-2

Mesh:

Substances:

Year:  2017        PMID: 28088469     DOI: 10.1016/j.mce.2017.01.016

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  2 in total

1.  Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells.

Authors:  Marianne S Andresen; Benedicte Stavik; Marit Sletten; Mari Tinholt; Per Morten Sandset; Nina Iversen; Grethe Skretting
Journal:  Sci Rep       Date:  2020-03-04       Impact factor: 4.379

Review 2.  A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance.

Authors:  Guan-Jun Yang; Yan-Jun Liu; Li-Jian Ding; Fan Tao; Ming-Hui Zhu; Zhen-Yuan Shi; Juan-Ming Wen; Meng-Yao Niu; Xiang Li; Zhan-Song Xu; Wan-Jia Qin; Chen-Jie Fei; Jiong Chen
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.